Teligent

Teligent develop, manufacture and market pharmaceutical products for use by doctors and patients in the United States and Canada.  They are a dynamic group of about 130 employees based in New Jersey, Toronto, Montreal and Tallinn, Estonia. Their Product Development and Manufacturing complex is in Buena, New Jersey, approximately 45 minutes from Philadelphia. In 2015 They acquired Alveda Pharmaceuticals Inc., a Toronto-based pharmaceutical company focused on the Canadian injectable pharmaceutical market. In 2016 They hired Their first European colleagues in Tallinn who support Their supply chain and quality operations.

VJGJ, Inc. engages in the development, manufacture, and market of topical and branded generic and generic injectable pharmaceutical products. It also provides contract manufacturing services to the pharmaceutical, over the counter, and cosmetic markets. The company was founded by Jane E. Hager on August 26, 1977 and is headquartered in Buena, NJ.

BUENA, N.J., Aug.  14, 2020  (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, announced they will hold a conference call at 8:00AM ET on Wednesday August 19th, 2020 to discuss the 2nd quarter 2020 financial results and business update.

Teligent, Inc. to Hold Conference Call for Second Quarter 2020 Financial Results and Business Update on Wednesday August 19th, 2020

BUENA, N.J., July  20, 2020  (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT) (“Teligent” or the “Company”), a New Jersey-based specialty generic pharmaceutical company, announced the closing of the issuance of $13.8 million aggregate principal amount of 9.5% Series C Senior Convertible Notes due 2023 (the “New 2023 Notes”). After taking into account an original issue discount and other transaction fees (including fees payable to the purchasers in the form of additional New 2023 Notes), the Company received approximately $10.0 million of net cash proceeds, which will be used to fund general corporate and working capital purposes.

Teligent Announces Completion of Series C Convertible Note Financing and Exchange

BUENA, N.J., July  20, 2020  (GLOBE NEWSWIRE) -- Teligent, Inc. (Nasdaq: TLGT) (“Teligent” or the “Company”), a New Jersey based specialty generic pharmaceutical company, is pleased to announce that John Celentano, a current independent director of Teligent, has been appointed Chairman of Teligent's Board of Directors, replacing James C. Gale who opted to not stand for reelection to Teligent’s board of directors in order to devote more time to other business interests.

Teligent, Inc. Announces the Appointment of John Celentano as Chairman of the Board

BUENA, N.J., July  17, 2020  (GLOBE NEWSWIRE) -- Teligent, Inc. (Nasdaq: TLGT) (“Teligent” or the “Company”), a New Jersey based specialty generic pharmaceutical company, today announced the hiring of Philip Yachmetz as Chief Legal Officer and Corporate Secretary of the Company, effective July 16, 2020.

Teligent, Inc. Announces Hiring of Chief Legal Officer and Corporate Secretary

BUENA, N.J., June  22, 2020  (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT) (“Teligent” or the “Company”), a New Jersey-based specialty generic pharmaceutical company, announced today that it received notice from The NASDAQ Stock Market LLC (“NASDAQ”) on June 18, 2020 indicating that the Company has regained compliance with NASDAQ Listing Rule 5450(a)(1), which requires the Company’s common stock to maintain a minimum bid price of $1.00 per share. The NASDAQ staff made this determination of compliance after the closing bid price of the Company’s common stock was at $1.00 per share or greater for the prior 10 consecutive business days.

Teligent Regains Compliance with NASDAQ Listing Requirements

BUENA, N.J., June  03, 2020  (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT) (“Teligent” or the “Company”), a New Jersey-based specialty generic pharmaceutical company, announced today conversion rate adjustments for the Company’s 7.0% Cash / 8.0% PIK Series B Senior Unsecured Convertible Notes Due 2023 (the “Series B Notes”) and its 4.75% Convertible Senior Notes Due 2023 (the “4.75% Notes”). The conversion rate adjustments are being made pursuant to the indentures governing the Series B Notes and 4.75% Notes as a result of the Company’s previously announced one-for-ten reverse stock split. Prior to the reverse stock split, the conversion rates were 1,388.889 shares of Common Stock per $1,000 principal amount of the Series B Notes and 224.7191 shares of Common Stock per $1,000 principal amount of the 4.75% Notes. As a result of the reverse stock split, effective immediately after the open of business on May 28, 2020, the conversion rates are 138.8897 shares of Common Stock per $1,000 principal amount of the Series B Notes and 22.4720 shares of Common Stock per $1,000 principal amount of the 4.75% Notes. Notice of the conversion rate adjustments was delivered to holders of the Series B Notes and 4.75% Notes and Wilmington Trust National Association, as trustee, in accordance with the terms of the indentures governing the Series B Notes and 4.75% Notes.

Teligent Announces Conversion Rate Adjustment for its 7.0% Cash / 8.0% PIK Series B Senior Unsecured Convertible Notes Due 2023 and its 4.75% Convertible Senior Notes Due 2023

BUENA, N.J., May  26, 2020  (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT) (“Teligent” or the “Company”), a New Jersey-based specialty generic pharmaceutical company, announced today that as of 12:01 a.m., Eastern Time, on May 28, 2020 it will effect a one-for-ten reverse stock split of its outstanding common stock, which will be effective for trading purposes as of the commencement of trading on Thursday, May 28, 2020. 

Teligent Announces One-for-Ten Reverse Stock Split

Teligent's (TLGT) CEO Tim Sawyer on Q1 2020 Results - Earnings Call Transcript

BUENA, N.J., May  22, 2020  (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced its financial results for the first quarter ended March 31, 2020.

Teligent, Inc. Announces First Quarter 2020 Results

Teligent, Inc. (TLGT) CEO Tim Sawyer on Q4 2019 Results - Earnings Call Transcript

Shares of Teligent (NASDAQ:TLGT) rose 11% in pre-market trading after the company reported Q4 results.

Recap: Teligent Q4 Earnings

BUENA, N.J., April  08, 2020  (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced its financial results for the fourth quarter and year ended December 31, 2019.

TELIGENT, INC. ANNOUNCES FOURTH QUARTER AND YEAR END 2019 RESULTS & AMENDMENTS TO EXISTING SECURED CREDIT FACILITIES

BUENA, N.J., Feb.  05, 2020  (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT) (“Teligent” or the “Company”), a New Jersey based specialty generic pharmaceutical company, today announced a transition in leadership.

Teligent, Inc. Announces Transition in Leadership

BUENA, N.J., Dec.  23, 2019  (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced its development partner has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for its abbreviated new drug application (ANDA) for its first complex drug indicated for an orphan disease population.  In the letter, the FDA requested further information and raw data to support the ANDA.

Teligent, Inc. Announces FDA Request for Further Data on Complex Drug

Teligent, Inc. (TLGT) CEO Jason Grenfell-Gardner on Q3 2019 Results - Earnings Call Transcript

Teligent (TLGT) delivered earnings and revenue surprises of -100.00% and -6.83%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Teligent (TLGT) Reports Q3 Loss, Misses Revenue Estimates

Teligent: 100% Upside Based On Revised SOTP With Several Near-Term Catalysts

BUENA, N.J., Oct.  28, 2019  (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT) (“Teligent” or the “Company”), a New Jersey-based specialty generic pharmaceutical company, announced the pricing of $34,405,000 aggregate principal amount of its 7.0% Cash / 8.0% PIK Series B Senior Unsecured Convertible Notes due 2023 (the “New 2023 Notes”).  It is expected that the offering will close on or about October 31, 2019, subject to customary closing conditions. 

Teligent Announces the Pricing of $34.4 Million of Series B Senior Convertible Notes

BUENA, N.J., Oct.  28, 2019  (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced that it has filed a prior approval supplement (PAS) for ranitidine hydrochloride injection. This is the planned first injectable product to be manufactured out of the newly completed expansion of its manufacturing site in Buena, NJ. As this is the first injectable filing related to the new expansion, the PAS review will be subject to a pre-approval inspection (PAI) of the manufacturing site by the FDA, which the Company expects to occur within four months of the date of the filing.

Teligent Announces First Injectable Filing From New Manufacturing Facility

BUENA, N.J., Oct.  18, 2019  (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced it has received approval of the Company’s abbreviated new drug application (ANDA) from the U.S. Food and Drug Administration (FDA) of Gentamicin Sulfate Cream USP, 0.1% (gentamicin base).  This is Teligent’s fifth approval of 2019, and its thirty-seventh approval from its internally-developed pipeline of topical generic pharmaceutical medicines.

Teligent, Inc. Announces FDA Approval of Gentamicin Sulfate Cream USP, 0.1% (Gentamicin Base)

BUENA, N.J., Oct.  01, 2019  (GLOBE NEWSWIRE) -- Teligent Inc. (Nasdaq: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced that it has retained SVB Leerink as its financial advisor to assist with a strategic review of assets non-core to the Company’s long-term strategy.

Teligent Announces Strategic Review

TLGT is a rapidly growing micro-cap specialty generic manufacturer with 200%+ upside potential over the next 12-18 months.

Teligent: Micro-Cap Specialty Generic Company With Several Significant Catalysts To Drive Substantial Upside

Teligent: Micro-Cap Specialty Generic

Teligent's (TLGT) CEO Jason Grenfell-Gardner on Q2 2019 Results - Earnings Call Transcript

Teligent (TLGT) delivered earnings and revenue surprises of 0.00% and 4.36%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

News for Teligent Stock (TLGT)